ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen VEXAS syndroom Richtlijnen en literatuur

Richtlijnen

Er is op dit moment geen richtlijn voor VEXAS syndroom. 

Literatuur

  1. Maas D. et al. Uw diagnose? Ned Tijdschr Hematol 2024; 21:349-51
  2. Beck D.B. et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med, 2020. 383(27): p.2628-2638
  3. Bruno A. et al. Autoimmune manifestations in VEXAS: opportunities for integration and pitfalls to interpretation. J Allergy Clin Immunol, 2023. 151(5): p. 1204-1214
  4. Koster M.J. et al. VEXAS syndrome: clinical, hematologic features and a practical approach to diagnosis and management. Am J Hematol, 2024. 99(2): p. 284-299
  5. Al-Hakim A. and Savic S. An update on VEXAS syndrome. Expert Rev Clin Immunol, 2023. 19(2): p. 203-215
  6. Heiblig M. et al. VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view. Best Practice & Research Clinical Rheumatology, 2023. 37(1): p. 101861
  7. Cherniawsky H. et al. VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation. Eur J Haematol, 2023. 110(6): p. 633-638
  8. Boyadzhieva Z. et al. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology (Oxford), 2023. 62(11): p. 3518-3525
  9. Bourbon E. et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood, 2021. 137(26): p. 3682-3684
  10. Heiblig M. et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood, 2022. 140(8): p. 927-931
  11. Comont T. et al.  Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol, 2022. 196(4): p. 969-974
  12. Mekinian  A. et al. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia, 2022. 36(11): p. 2739-2742
  13. Raaijmakers M. et al. Azacytidine treatment for VEXAS syndrome. Hemasphere, 2021. 5(12): p. e661
  14. Aalbers AM et al. Long-term genetic and clinical remission after cessation of azacitidine treatment in patients with VEXAS syndrome. HemaSphere, 2024. e129
  15. Sujobert P. et al. VEXAS: where do we stand 2 years later. Current Opinion Hematology, 2023 30:64-69

 

Ga terug naar de VEXAS syndroom homepage of lees meer over VEXAS syndroom:

Ga terug naar de algemene homepage Behandelprotocollen.